


JANEWAY'S



Garland Science


9TH EDITION

IMMUNOBIOLOGY



KENNETH MURPHY & CASEY WEAVER

Icons used throughout the book



JANEWAY'S

IMMUNO BIOLOGY

9TH EDITION

This page intentionally left blank
to match pagination of print book

JANEWAY'S

IMMUNO BIOLOGY

9TH EDITION

Kenneth Murphy

Washington University School of Medicine, St. Louis

Casey Weaver

University of Alabama at Birmingham, School of Medicine

With contributions by:

Allan Mowat

University of Glasgow

Leslie Berg

University of Massachusetts Medical School

David Chaplin

University of Alabama at Birmingham, School of Medicine

With acknowledgment to:

Charles A. Janeway Jr.

Paul Travers

MRC Centre for Regenerative Medicine, Edinburgh

Mark Walport



Garland Science

Taylor & Francis Group

NEW YORK AND LONDON

Vice President: Denise Schanck
Development Editor: Monica Toledo
Associate Editor: Allie Bochicchio
Assistant Editor: Claudia Acevedo-Quiriones
Text Editor: Elizabeth Zayetz
Production Editor: Deepa Divakaran
Typesetter: Deepa Divakaran and EJ Publishing Services
Illustrator and Design: Matthew McClements, Blink Studio, Ltd.
Copyeditor: Richard K. Mickey
Proofreader: Sally Livitt
Permission Coordinator: Sheri Gilbert
Indexer: Medical Indexing Ltd.

© 2017 by Garland Science, Taylor & Francis Group, LLC

This book contains information obtained from authentic and highly regarded sources. Every effort has been made to trace copyright holders and to obtain their permission for the use of copyright material. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems—without permission of the copyright holder.

ISBN 978-0-8153-4505-3 978-0-8153-4551-0 (International Paperback)

Library of Congress Cataloging-in-Publication Data

Names: Murphy, Kenneth (Kenneth M.), author. | Weaver, Casey, author.
Title: Janeway's immunobiology / Kenneth Murphy, Casey Weaver ; with contributions by Allan Mowat, Leslie Berg, David Chaplin ; with acknowledgment to Charles A. Janeway Jr., Paul Travers, Mark Walport.
Other titles: Immunobiology
Description: 9th edition. | New York, NY : Garland Science/Taylor & Francis Group, LLC, [2016] | Includes bibliographical references and index.
Identifiers: LCCN 2015050960 | ISBN 9780815345053 (pbk.) | ISBN 9780815345510 (pbk.-ROW) | ISBN 9780815345503 (looseleaf)
Subjects: | MESH: Immune System--physiology | Immune System--physiopathology | Immunity | Immunotherapy
Classification: LCC QR181 | NLM QW 504 | DDC 616.07/9--dc23
LC record available at <http://lccn.loc.gov/2015050960>

Published by Garland Science, Taylor & Francis Group, LLC, an informa business,
711 Third Avenue, New York, NY, 10017, USA, and 3 Park Square, Milton Park, Abingdon,
OX14 4RN, UK.

Printed in the United States of America

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1



Visit our web site at <http://www.garlandscience.com>

Preface

Janeway's Immunobiology is intended for undergraduate and graduate courses and for medical students, but its depth and scope also make it a useful resource for trainees and practicing immunologists. Its narrative takes the host's perspective in the struggle with the microbial world—a viewpoint distinguishing ‘immunology’ from ‘microbiology’. Other facets of immunology, such as autoimmunity, immunodeficiencies, allergy, transplant rejection, and new aspects of cancer immunotherapy are also covered in depth, and a companion book, *Case Studies in Immunology*, provides clinical examples of immune-related disease. In *Immunobiology*, symbols in the margin indicate where the basic immunological concepts related to *Case Studies* are discussed.

The ninth edition retains the previous organization of five major sections and sixteen chapters, but reorganizes content to clarify presentation and eliminate redundancies, updating each chapter and adding over 100 new figures. The first section (Chapters 1–3) includes the latest developments in innate sensing mechanisms and covers new findings in innate lymphoid cells and the concept of ‘immune effector modules’ that is used throughout the rest of the book. Coverage of chemokine networks has been updated throughout (Chapters 3 and 11). The second section (Chapters 4–6) adds new findings for $\gamma\delta$ T cell recognition and for the targeting of activation-induced cytidine deaminase (AID) class switch recombination. The third section (Chapters 7 and 8) is extensively updated and covers new material on integrin activation, cytoskeletal reorganization, and Akt and mTOR signaling. The fourth section enhances coverage of CD4 T cell subsets (Chapter 9), including follicular helper T cells that regulate switching and affinity maturation (Chapter 10). Chapter 11 now organizes innate and adaptive responses to pathogens around the effector module concept, and features new findings for tissue-resident memory T cells. Chapter 12 has been thoroughly updated to keep pace with the quickly advancing field of mucosal immunity. In the last section, coverage of primary and secondary immunodeficiencies has been reorganized and updated with an expanded treatment of immune evasion by pathogens and HIV/AIDS (Chapter 13). Updated and more detailed consideration of allergy and allergic diseases are presented in Chapter 14, and for autoimmunity and transplantation in Chapter 15. Finally, Chapter 16 has expanded coverage of new breakthroughs in cancer immunotherapy, including ‘checkpoint blockade’ and chimeric antigen receptor (CAR) T-cell therapies.

End-of-chapter review questions have been completely updated in the ninth edition, posed in a variety of formats, with answers available online. Appendix I: The Immunologist's Toolbox has undergone a comprehensive

revitalization with the addition of many new techniques, including the CRISPR/Cas9 system and mass spectrometry/proteomics. Finally, a new Question Bank has been created to aid instructors in the development of exams that require the student to reflect upon and synthesize concepts in each chapter.

Once again, we benefited from the expert revision of Chapter 12 by Allan Mowat, and from contributions of two new contributors, David Chaplin and Leslie Berg. David's combined clinical and basic immunologic strengths greatly improved Chapter 14, and Leslie applied her signaling expertise to Chapters 7 and 8, and Appendix I, and her strength as an educator in creating the new Question Bank for instructors. Many people deserve special thanks. Gary Grajales wrote all end-of-chapter questions. New for this edition, we enlisted input from our most important audience and perhaps best critics—students of immunology-in-training who provided feedback on drafts of individual chapters, and Appendices II–IV. We benefitted from our thoughtful colleagues who reviewed the eighth edition. They are credited in the Acknowledgments section; we are indebted to them all.

We have the good fortune to work with an outstanding group at Garland Science. We thank Monica Toledo, our development editor, who coordinated the entire project, guiding us gently but firmly back on track throughout the process, with efficient assistance from Allie Bochicchio and Claudia Acevedo-Quinones. We thank Denise Schanck, our publisher, who, as always, contributed her guidance, support, and wisdom. We thank Adam Sendroff, who is instrumental in relaying information about the book to immunologists around the world. As in all previous editions, Matt McClements has contributed his genius—and patience—re-interpreting authors' sketches into elegant illustrations. We warmly welcome our new text editor Elizabeth Zayetz, who stepped in for Eleanor Lawrence, our previous editor, and guiding light. The authors wish to thank their most important partners—Theresa and Cindy Lou—colleagues in life who have supported this effort with their generosity of time, their own editorial insights, and their infinite patience.

As temporary stewards of Charlie's legacy, *Janeway's Immunobiology*, we hope this ninth edition will continue to inspire—as he did—students to appreciate immunology's beautiful subtlety. We encourage all readers to share with us their views on where we have come up short, so the next edition will further approach the asymptote. Happy reading!

Kenneth Murphy
Casey Weaver

Resources for Instructors and Students

The teaching and learning resources for instructors and students are available online. The homework platform is available to interested instructors and their students. Instructors will need to set up student access in order to use the dashboard to track student progress on assignments. The instructor's resources on the Garland Science website are password-protected and available only to adopting instructors. The student resources on the Garland Science website are available to everyone. We hope these resources will enhance student learning and make it easier for instructors to prepare dynamic lectures and activities for the classroom.

Online Homework Platform with Instructor Dashboard

Instructors can obtain access to the online homework platform from their sales representative or by emailing science@garland.com. Students who wish to use the platform must purchase access and, if required for class, obtain a course link from their instructor.

The online homework platform is designed to improve and track student performance. It allows instructors to select homework assignments on specific topics and review the performance of the entire class, as well as individual students, via the instructor dashboard. The user-friendly system provides a convenient way to gauge student progress, and tailor classroom discussion, activities, and lectures to areas that require specific remediation. The features and assignments include:

- *Instructor Dashboard* displays data on student performance: such as responses to individual questions and length of time spent to complete assignments.
- *Tutorials* explain essential or difficult concepts and are integrated with a variety of questions that assess student engagement and mastery of the material.

The tutorials were created by Stacey A. Gorski, University of the Sciences in Philadelphia.

Instructor Resources

Instructor Resources are available on the Garland Science Instructor's Resource Site, located at www.garlandscience.com/instructors. The website provides access not only to the teaching resources for this book but also to all other Garland Science textbooks. Adopting instructors can obtain access to the site from their sales representative or by emailing science@garland.com.

Art of Janeway's Immunobiology, Ninth Edition

The images from the book are available in two convenient formats: PowerPoint® and JPEG. They have been optimized for display on a computer. Figures are searchable by figure number, by figure name, or by keywords used in the figure legend from the book.

Figure-Integrated Lecture Outlines

The section headings, concept headings, and figures from the text have been integrated into PowerPoint®

presentations. These will be useful for instructors who would like a head start creating lectures for their course. Like all of our PowerPoint® presentations, the lecture outlines can be customized. For example, the content of these presentations can be combined with videos and questions from the book or Question Bank, in order to create unique lectures that facilitate interactive learning.

Animations and Videos

The animations and videos that are available to students are also available on the Instructor's Website in two formats. The WMV-formatted movies are created for instructors who wish to use the movies in PowerPoint® presentations on Windows® computers; the QuickTime-formatted movies are for use in PowerPoint® for Apple computers or Keynote® presentations. The movies can easily be downloaded using the 'download' button on the movie preview page. The movies are related to specific chapters and callouts to the movies are highlighted in color throughout the textbook.

Question Bank

Written by Leslie Berg, University of Massachusetts Medical School, the Question Bank includes a variety of question formats: multiple choice, fill-in-the-blank, true-false, matching, essay, and challenging synthesis questions. There are approximately 30–40 questions per chapter, and a large number of the multiple-choice questions will be suitable for use with personal response systems (that is, clickers). The Question Bank provides a comprehensive sampling of questions that require the student to reflect upon and integrate information, and can be used either directly or as inspiration for instructors to write their own test questions.

Student Resources

The resources for students are available on the *Janeway's Immunobiology* Student Website, located at students.garlandscience.com.

Answers to End-of-Chapter Questions

Answers to the end-of-chapter questions are available to students for self-testing.

Animations and Videos

There are over 40 narrated movies, covering a range of immunology topics, which review key concepts and illuminate the experimental process.

Flashcards

Each chapter contains flashcards, built into the student website, that allow students to review key terms from the text.

Glossary

The comprehensive glossary of key terms from the book is online and can be searched or browsed.

Acknowledgments

We would like to thank the following experts who read parts or the whole of the eighth edition chapters and provided us with invaluable advice in developing this new edition.

Chapter 2: Teizo Fujita, Fukushima Prefectural General Hygiene Institute; Thad Stappenbeck, Washington University; Andrea J. Tenner, University of California, Irvine.

Chapter 3: Shizuo Akira, Osaka University; Mary Dinauer, Washington University in St. Louis; Lewis Lanier, University of California, San Francisco; Gabriel Nuñez, University of Michigan Medical School; David Raulet, University of California, Berkeley; Caetano Reis e Sousa, Cancer Research UK; Tadatsugu Taniguchi, University of Tokyo; Eric Vivier, Université de la Méditerranée Campus de Luminy; Wayne Yokoyama, Washington University.

Chapter 4: Chris Garcia, Stanford University; Ellis Reinherz, Harvard Medical School; Robyn Stanfield, The Scripps Research Institute; Ian Wilson, The Scripps Research Institute.

Chapter 5: Michael Lieber, University of Southern California Norris Cancer Center; Michel Neuberger, University of Cambridge; David Schatz, Yale University School of Medicine; Barry Sleckman, Washington University School of Medicine, St. Louis; Philip Tucker, University of Texas, Austin.

Chapter 6: Sebastian Amigorena, Institut Curie; Siamak Bahram, Centre de Recherche d'Immunologie et d'Hématologie; Peter Cresswell, Yale University School of Medicine; Mitchell Kronenberg, La Jolla Institute for Allergy & Immunology; Philippa Marrack, National Jewish Health; Hans-Georg Rammensee, University of Tuebingen, Germany; Jose Villadangos, University of Melbourne; Ian Wilson, The Scripps Research Institute.

Chapter 7: Oreste Acuto, University of Oxford; Francis Chan, University of Massachusetts Medical School; Vigo Heissmeyer, Helmholtz Center Munich; Steve Jameson, University of Minnesota; Pamela L. Schwartzberg, NIH; Art Weiss, University of California, San Francisco.

Chapter 8: Michael Cancro, University of Pennsylvania School of Medicine; Robert Carter, University of Alabama; Ian Crispe, University of Washington; Kris Hogquist, University of Minnesota; Eric Huseby, University of Massachusetts Medical School; Joonsoo Kang, University of Massachusetts Medical School; Ellen Robey, University of California, Berkeley; Nancy Ruddle, Yale University School of Medicine; Juan Carlos Zúñiga-Pflücker, University of Toronto.

Chapter 9: Francis Carbone, University of Melbourne; Shane Crotty, La Jolla Institute of Allergy and Immunology; Bill Heath, University of Melbourne, Victoria; Marc Jenkins, University of Minnesota; Alexander Rudensky, Memorial Sloan Kettering Cancer Center; Shimon Sakaguchi, Osaka University.

Chapter 10: Michael Cancro, University of Pennsylvania School of Medicine; Ann Haberman, Yale University

School of Medicine; John Kearney, University of Alabama at Birmingham; Troy Randall, University of Alabama at Birmingham; Jeffrey Ravetch, Rockefeller University; Haley Tucker, University of Texas at Austin.

Chapter 11: Susan Kaeck, Yale University School of Medicine; Stephen McSorley, University of California, Davis.

Chapter 12: Nadine Cerf-Bensussan, Université Paris Descartes-Sorbonne, Paris; Thomas MacDonald, Barts and London School of Medicine and Dentistry; Maria Rescigno, European Institute of Oncology; Michael Russell, University at Buffalo; Thad Stappenbeck, Washington University.

Chapter 13: Mary Collins, University College London; Paul Goepfert, University of Alabama at Birmingham; Paul Klenerman, University of Oxford; Warren Leonard, National Heart, Lung, and Blood Institute, NIH; Luigi Notarangelo, Boston Children's Hospital; Sarah Rowland-Jones, Oxford University; Harry Schroeder, University of Alabama at Birmingham.

Chapter 14: Cezmi A. Akdis, Swiss Institute of Allergy and Asthma Research; Larry Borish, University of Virginia Health System; Barry Kay, National Heart and Lung Institute; Harald Renz, Philipps University Marburg; Robert Schleimer, Northwestern University; Dale Umetsu, Genentech.

Chapter 15: Anne Davidson, The Feinstein Institute for Medical Research; Robert Fairchild, Cleveland Clinic; Rikard Holmdahl, Karolinska Institute; Fadi Lakkis, University of Pittsburgh; Ann Marshak-Rothstein, University of Massachusetts Medical School; Carson Moseley, University of Alabama at Birmingham; Luigi Notarangelo, Boston Children's Hospital; Noel Rose, Johns Hopkins Bloomberg School of Public Health; Warren Shlomchik, University of Pittsburgh School of Medicine; Laurence Turka, Harvard Medical School.

Chapter 16: James Crowe, Vanderbilt University; Glenn Dranoff, Dana-Farber Cancer Institute; Thomas Gajewski, University of Chicago; Carson Moseley, University of Alabama at Birmingham; Caetano Reis e Sousa, Cancer Research UK.

Appendix I: Lawrence Stern, University of Massachusetts Medical School.

We would also like to specially acknowledge and thank the students: Alina Petris, University of Manchester; Carlos Briseno, Washington University in St. Louis; Daniel DiToro, University of Alabama at Birmingham; Vivek Durai, Washington University in St. Louis; Wilfredo Garcia, Harvard University; Nichole Escalante, University of Toronto; Kate Jackson, University of Manchester; Isil Mirzanli, University of Manchester; Carson Moseley, University of Alabama at Birmingham; Daniel Silberger, University of Alabama at Birmingham; Jeffrey Singer, University of Alabama at Birmingham; Deepica Stephen, University of Manchester; Mayra Cruz Tleugabulova, University of Toronto.

This page intentionally left blank
to match pagination of print book

Contents

PART I AN INTRODUCTION TO IMMUNOBIOLOGY AND INNATE IMMUNITY

Chapter 1	Basic Concepts in Immunology	1
Chapter 2	Innate Immunity: The First Lines of Defense	37
Chapter 3	The Induced Response of Innate Immunity	77

PART II THE RECOGNITION OF ANTIGEN

Chapter 4	Antigen Recognition by B-cell and T-cell Receptors	139
Chapter 5	The Generation of Lymphocyte Antigen Receptors	173
Chapter 6	Antigen Presentation to T Lymphocytes	213

PART III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES

Chapter 7	Lymphocyte Receptor Signaling	257
Chapter 8	The Development of B and T Lymphocytes	295

PART IV THE ADAPTIVE IMMUNE RESPONSE

Chapter 9	T-cell-Mediated Immunity	345
Chapter 10	The Humoral Immune Response	399
Chapter 11	Integrated Dynamics of Innate and Adaptive Immunity	445
Chapter 12	The Mucosal Immune System	493

PART V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 13	Failures of Host Defense Mechanisms	533
Chapter 14	Allergy and Allergic Diseases	601
Chapter 15	Autoimmunity and Transplantation	643
Chapter 16	Manipulation of the Immune Response	701

APPENDICES

I	The Immunologist's Toolbox	749
II	CD antigens	791
III	Cytokines and their Receptors	811
IV	Chemokines and their Receptors	814

	Biographies	816
	Glossary	818
	Index	855

Detailed Contents

PART I AN INTRODUCTION TO IMMUNO-BIOLOGY AND INNATE IMMUNITY

Chapter 1 Basic Concepts in Immunology

The origins of vertebrate immune cells.

Principles of innate immunity.

- 1-1 Commensal organisms cause little host damage while pathogens damage host tissues by a variety of mechanisms.
- 1-2 Anatomic and chemical barriers are the first defense against pathogens.
- 1-3 The immune system is activated by inflammatory inducers that indicate the presence of pathogens or tissue damage.
- 1-4 The myeloid lineage comprises most of the cells of the innate immune system.
- 1-5 Sensor cells express pattern recognition receptors that provide an initial discrimination between self and nonself.
- 1-6 Sensor cells induce an inflammatory response by producing mediators such as chemokines and cytokines.
- 1-7 Innate lymphocytes and natural killer cells are effector cells that share similarities with lymphoid lineages of the adaptive immune system.

Summary.

Principles of adaptive immunity.

- 1-8 The interaction of antigens with antigen receptors induces lymphocytes to acquire effector and memory activity.
- 1-9 Antibodies and T-cell receptors are composed of constant and variable regions that provide distinct functions.
- 1-10 Antibodies and T-cell receptors recognize antigens by fundamentally different mechanisms.
- 1-11 Antigen-receptor genes are assembled by somatic gene rearrangements of incomplete receptor gene segments.
- 1-12 Lymphocytes activated by antigen give rise to clones of antigen-specific effector cells that mediate adaptive immunity.
- 1-13 Lymphocytes with self-reactive receptors are normally eliminated during development or are functionally inactivated.
- 1-14 Lymphocytes mature in the bone marrow or the thymus and then congregate in lymphoid tissues throughout the body.
- 1-15 Adaptive immune responses are initiated by antigen and antigen-presenting cells in secondary lymphoid tissues.
- 1-16 Lymphocytes encounter and respond to antigen in the peripheral lymphoid organs.
- 1-17 Mucosal surfaces have specialized immune structures that orchestrate responses to environmental microbial encounters.

- 1-18 Lymphocytes activated by antigen proliferate in the peripheral lymphoid organs, generating effector cells and immunological memory. 23
- Summary. 24
- The effector mechanisms of immunity. 25**
- 1-19 Innate immune responses can select from several effector modules to protect against different types of pathogens. 26
- 1-20 Antibodies protect against extracellular pathogens and their toxic products. 27
- 1-21 T cells orchestrate cell-mediated immunity and regulate B-cell responses to most antigens. 29
- 1-22 Inherited and acquired defects in the immune system result in increased susceptibility to infection. 31
- 1-23 Understanding adaptive immune responses is important for the control of allergies, autoimmune disease, and the rejection of transplanted organs. 32
- 1-24 Vaccination is the most effective means of controlling infectious diseases. 33
- Summary. 34
- Summary to Chapter 1. 34
- Questions. 35
- References. 36

Chapter 2 Innate Immunity: The First Lines of Defense 37

Anatomic barriers and initial chemical defenses. 38

- 2-1 Infectious diseases are caused by diverse living agents that replicate in their hosts. 38
- 2-2 Epithelial surfaces of the body provide the first barrier against infection. 42
- 2-3 Infectious agents must overcome innate host defenses to establish a focus of infection. 44
- 2-4 Epithelial cells and phagocytes produce several kinds of antimicrobial proteins. 45
- Summary. 48
- The complement system and innate immunity. 49**
- 2-5 The complement system recognizes features of microbial surfaces and marks them for destruction by coating them with C3b. 50
- 2-6 The lectin pathway uses soluble receptors that recognize microbial surfaces to activate the complement cascade. 53
- 2-7 The classical pathway is initiated by activation of the C1 complex and is homologous to the lectin pathway. 56
- 2-8 Complement activation is largely confined to the surface on which it is initiated. 57
- 2-9 The alternative pathway is an amplification loop for C3b formation that is accelerated by properdin in the presence of pathogens. 58
- 2-10 Membrane and plasma proteins that regulate the formation and stability of C3 convertases determine the extent of complement activation. 60

2-11	Complement developed early in the evolution of multicellular organisms.	61	3-14	TLR and NOD genes have undergone extensive diversification in both invertebrates and some primitive chordates.	106
2-12	Surface-bound C3 convertase deposits large numbers of C3b fragments on pathogen surfaces and generates C5 convertase activity.	62		Summary.	106
2-13	Ingestion of complement-tagged pathogens by phagocytes is mediated by receptors for the bound complement proteins.	63		Induced innate responses to infection.	107
2-14	The small fragments of some complement proteins initiate a local inflammatory response.	65	3-15	Cytokines and their receptors fall into distinct families of structurally related proteins.	107
2-15	The terminal complement proteins polymerize to form pores in membranes that can kill certain pathogens.	66	3-16	Cytokine receptors of the hematopoietin family are associated with the JAK family of tyrosine kinases, which activate STAT transcription factors.	109
2-16	Complement control proteins regulate all three pathways of complement activation and protect the host from their destructive effects.	67	3-17	Chemokines released by macrophages and dendritic cells recruit effector cells to sites of infection.	111
2-17	Pathogens produce several types of proteins that can inhibit complement activation.	71	3-18	Cell-adhesion molecules control interactions between leukocytes and endothelial cells during an inflammatory response.	113
	Summary.	72	3-19	Neutrophils make up the first wave of cells that cross the blood vessel wall to enter an inflamed tissue.	116
	Summary to Chapter 2.	73	3-20	TNF- α is an important cytokine that triggers local containment of infection but induces shock when released systemically.	118
	Questions.	74	3-21	Cytokines made by macrophages and dendritic cells induce a systemic reaction known as the acute-phase response.	118
	References.	75	3-22	Interferons induced by viral infection make several contributions to host defense.	121
	Chapter 3 The Induced Responses of Innate Immunity	77	3-23	Several types of innate lymphoid cells provide protection in early infection.	124
	Pattern recognition by cells of the innate immune system.	77	3-24	NK cells are activated by type I interferon and macrophage-derived cytokines.	125
3-1	After entering tissues, many microbes are recognized, ingested, and killed by phagocytes.	78	3-25	NK cells express activating and inhibitory receptors to distinguish between healthy and infected cells.	126
3-2	G-protein-coupled receptors on phagocytes link microbe recognition with increased efficiency of intracellular killing.	81	3-26	NK-cell receptors belong to several structural families, the KIRs, KLRs, and NCRs.	128
3-3	Microbial recognition and tissue damage initiate an inflammatory response.	85	3-27	NK cells express activating receptors that recognize ligands induced on infected cells or tumor cells.	130
3-4	Toll-like receptors represent an ancient pathogen-recognition system.	87		Summary.	131
3-5	Mammalian Toll-like receptors are activated by many different pathogen-associated molecular patterns.	88		Summary to Chapter 3.	131
3-6	TLR-4 recognizes bacterial lipopolysaccharide in association with the host accessory proteins MD-2 and CD14.	92		Questions.	132
3-7	TLRs activate NF κ B, AP-1, and IRF transcription factors to induce the expression of inflammatory cytokines and type I interferons.	92		References.	133
3-8	The NOD-like receptors are intracellular sensors of bacterial infection and cellular damage.	96		PART II THE RECOGNITION OF ANTIGEN	
3-9	NLRP proteins react to infection or cellular damage through an inflammasome to induce cell death and inflammation.	98		Chapter 4 Antigen Recognition by B-cell and T-cell Receptors	139
3-10	The RIG-I-like receptors detect cytoplasmic viral RNAs and activate MAVS to induce type I interferon production and pro-inflammatory cytokines.	101		The structure of a typical antibody molecule.	140
3-11	Cytosolic DNA sensors signal through STING to induce production of type I interferons.	103	4-1	IgG antibodies consist of four polypeptide chains.	141
3-12	Activation of innate sensors in macrophages and dendritic cells triggers changes in gene expression that have far-reaching effects on the immune response.	104	4-2	Immunoglobulin heavy and light chains are composed of constant and variable regions.	142
3-13	Toll signaling in <i>Drosophila</i> is downstream of a distinct set of pathogen-recognition molecules.	105	4-3	The domains of an immunoglobulin molecule have similar structures.	142
			4-4	The antibody molecule can readily be cleaved into functionally distinct fragments.	144
			4-5	The hinge region of the immunoglobulin molecule allows flexibility in binding to multiple antigens.	145
				Summary.	145

The interaction of the antibody molecule with specific antigen.

4-6	Localized regions of hypervariable sequence form the antigen-binding site.	146
4-7	Antibodies bind antigens via contacts in CDRs that are complementary to the size and shape of the antigen.	147
4-8	Antibodies bind to conformational shapes on the surfaces of antigens using a variety of noncovalent forces.	148
4-9	Antibody interaction with intact antigens is influenced by steric constraints.	150
4-10	Some species generate antibodies with alternative structures.	151
	Summary.	152

Antigen recognition by T cells.

4-11	The TCR α : β heterodimer is very similar to a Fab fragment of immunoglobulin.	153
4-12	A T-cell receptor recognizes antigen in the form of a complex of a foreign peptide bound to an MHC molecule.	155
4-13	There are two classes of MHC molecules with distinct subunit compositions but similar three-dimensional structures.	155
4-14	Peptides are stably bound to MHC molecules, and also serve to stabilize the MHC molecule on the cell surface.	158
4-15	MHC class I molecules bind short peptides of 8–10 amino acids by both ends.	158
4-16	The length of the peptides bound by MHC class II molecules is not constrained.	160
4-17	The crystal structures of several peptide:MHC:T-cell receptor complexes show a similar orientation of the T-cell receptor over the peptide:MHC complex.	161
4-18	The CD4 and CD8 cell-surface proteins of T cells directly contact MHC molecules and are required to make an effective response to antigen.	163
4-19	The two classes of MHC molecules are expressed differentially on cells.	166
4-20	A distinct subset of T cells bears an alternative receptor made up of γ and δ chains.	166
	Summary.	167
	Summary to Chapter 4.	168
	Questions.	169
	References.	170

Chapter 5 The Generation of Lymphocyte Antigen Receptors

Primary immunoglobulin gene rearrangement.

5-1	Immunoglobulin genes are rearranged in the progenitors of antibody-producing cells.	174
5-2	Complete genes that encode a variable region are generated by the somatic recombination of separate gene segments.	175
5-3	Multiple contiguous V gene segments are present at each immunoglobulin locus.	176
5-4	Rearrangement of V, D, and J gene segments is guided by flanking DNA sequences.	178
5-5	The reaction that recombines V, D, and J gene segments involves both lymphocyte-specific and ubiquitous DNA-modifying enzymes.	179

5-6	The diversity of the immunoglobulin repertoire is generated by four main processes.	184
5-7	The multiple inherited gene segments are used in different combinations.	184
5-8	Variable addition and subtraction of nucleotides at the junctions between gene segments contributes to the diversity of the third hypervariable region.	185
	Summary.	186

T-cell receptor gene rearrangement.

5-9	The T-cell receptor gene segments are arranged in a similar pattern to immunoglobulin gene segments and are rearranged by the same enzymes.	187
5-10	T-cell receptors concentrate diversity in the third hypervariable region.	189
5-11	γ : δ T-cell receptors are also generated by gene rearrangement.	190
	Summary.	191

Structural variation in immunoglobulin constant regions.

5-12	Different classes of immunoglobulins are distinguished by the structure of their heavy-chain constant regions.	192
5-13	The constant region confers functional specialization on the antibody.	193
5-14	IgM and IgD are derived from the same pre-mRNA transcript and are both expressed on the surface of mature B cells.	194
5-15	Transmembrane and secreted forms of immunoglobulin are generated from alternative heavy-chain mRNA transcripts.	195
5-16	IgM and IgA can form polymers by interacting with the J chain.	197
	Summary.	198

Evolution of the adaptive immune response.

5-17	Some invertebrates generate extensive diversity in a repertoire of immunoglobulin-like genes.	198
5-18	Agnathans possess an adaptive immune system that uses somatic gene rearrangement to diversify receptors built from LRR domains.	200
5-19	RAG-dependent adaptive immunity based on a diversified repertoire of immunoglobulin-like genes appeared abruptly in the cartilaginous fishes.	202
5-20	Different species generate immunoglobulin diversity in different ways.	203
5-21	Both α : β and γ : δ T-cell receptors are present in cartilaginous fishes.	206
5-22	MHC class I and class II molecules are also first found in the cartilaginous fishes.	206
	Summary.	207
	Summary to Chapter 5.	207
	Questions.	208
	References.	209

Chapter 6 Antigen Presentation to T Lymphocytes

The generation of α : β T-cell receptor ligands.

6-1	Antigen presentation functions both in arming effector T cells and in triggering their effector functions to attack pathogen-infected cells.	214
-----	--	-----

6-2	Peptides are generated from ubiquitinated proteins in the cytosol by the proteasome.	216	7-1	Transmembrane receptors convert extracellular signals into intracellular biochemical events.	258
6-3	Peptides from the cytosol are transported by TAP into the endoplasmic reticulum and further processed before binding to MHC class I molecules.	218	7-2	Intracellular signal propagation is mediated by large multiprotein signaling complexes.	260
6-4	Newly synthesized MHC class I molecules are retained in the endoplasmic reticulum until they bind a peptide.	219	7-3	Small G proteins act as molecular switches in many different signaling pathways.	262
6-5	Dendritic cells use cross-presentation to present exogenous proteins on MHC class I molecules to prime CD8 T cells.	222	7-4	Signaling proteins are recruited to the membrane by a variety of mechanisms.	262
6-6	Peptide:MHC class II complexes are generated in acidified endocytic vesicles from proteins obtained through endocytosis, phagocytosis, and autophagy.	223	7-5	Post-translational modifications of proteins can both activate and inhibit signaling responses.	263
6-7	The invariant chain directs newly synthesized MHC class II molecules to acidified intracellular vesicles.	225	7-6	The activation of some receptors generates small-molecule second messengers.	264
6-8	The MHC class II-like molecules HLA-DM and HLA-DO regulate exchange of CLIP for other peptides.	226		Summary.	265
6-9	Cessation of antigen processing occurs in dendritic cells after their activation through reduced expression of the MARCH-1 E3 ligase.	229		Antigen receptor signaling and lymphocyte activation.	265
	Summary.	230	7-7	Antigen receptors consist of variable antigen-binding chains associated with invariant chains that carry out the signaling function of the receptor.	266
	The major histocompatibility complex and its function.	231	7-8	Antigen recognition by the T-cell receptor and its co-receptors transduces a signal across the plasma membrane to initiate signaling.	267
6-10	Many proteins involved in antigen processing and presentation are encoded by genes within the MHC.	231	7-9	Antigen recognition by the T-cell receptor and its co-receptors leads to phosphorylation of ITAMs by Src-family kinases, generating the first intracellular signal in a signaling cascade.	268
6-11	The protein products of MHC class I and class II genes are highly polymorphic.	234	7-10	Phosphorylated ITAMs recruit and activate the tyrosine kinase ZAP-70.	270
6-12	MHC polymorphism affects antigen recognition by T cells by influencing both peptide binding and the contacts between T-cell receptor and MHC molecule.	235	7-11	ITAMs are also found in other receptors on leukocytes that signal for cell activation.	270
6-13	Alloreactive T cells recognizing nonself MHC molecules are very abundant.	239	7-12	Activated ZAP-70 phosphorylates scaffold proteins and promotes PI 3-kinase activation.	271
6-14	Many T cells respond to superantigens.	240	7-13	Activated PLC- γ generates the second messengers diacylglycerol and inositol triphosphate that lead to transcription factor activation.	272
6-15	MHC polymorphism extends the range of antigens to which the immune system can respond.	241	7-14	Ca ²⁺ entry activates the transcription factor NFAT.	273
	Summary.	242	7-15	Ras activation stimulates the mitogen-activated protein kinase (MAPK) relay and induces expression of the transcription factor AP-1.	274
	Generation of ligands for unconventional T-cell subsets.	242	7-16	Protein kinase C activates the transcription factors NF- κ B and AP-1.	276
6-16	A variety of genes with specialized functions in immunity are also encoded in the MHC.	243	7-17	PI 3-kinase activation upregulates cellular metabolic pathways via the serine/threonine kinase Akt.	277
6-17	Specialized MHC class I molecules act as ligands for the activation and inhibition of NK cells and unconventional T-cell subsets.	245	7-18	T-cell receptor signaling leads to enhanced integrin-mediated cell adhesion.	278
6-18	Members of the CD1 family of MHC class I-like molecules present microbial lipids to invariant NKT cells.	246	7-19	T-cell receptor signaling induces cytoskeletal reorganization by activating the small GTPase Cdc42.	279
6-19	The nonclassical MHC class I molecule MR1 presents microbial folate metabolites to MAIT cells.	248	7-20	The logic of B-cell receptor signaling is similar to that of T-cell receptor signaling, but some of the signaling components are specific to B cells.	279
6-20	$\gamma\delta$ T cells can recognize a variety of diverse ligands.	249		Summary.	282
	Summary.	250		Co-stimulatory and inhibitory receptors modulate antigen receptor signaling in T and B lymphocytes.	282
	Summary to Chapter 6.	250	7-21	The cell-surface protein CD28 is a required co-stimulatory signaling receptor for naive T-cell activation.	283
	Questions.	251	7-22	Maximal activation of PLC- γ , which is important for transcription factor activation, requires a co-stimulatory signal induced by CD28.	284
	References.	252	7-23	TNF receptor superfamily members augment T-cell and B-cell activation.	284
PART III THE DEVELOPMENT OF MATURE LYMPHOCYTE RECEPTOR REPERTOIRES					
Chapter 7 Lymphocyte Receptor Signaling			257		
General principles of signal transduction and propagation.			257		

7-24	Inhibitory receptors on lymphocytes downregulate immune responses by interfering with co-stimulatory signaling pathways.	286	8-18	T-cell α -chain genes undergo successive rearrangements until positive selection or cell death intervenes.	326
7-25	Inhibitory receptors on lymphocytes downregulate immune responses by recruiting protein or lipid phosphatases.	287	Summary.	328	
Summary.		288	Positive and negative selection of T cells.	328	
Summary to Chapter 7.		289	8-19	Only thymocytes whose receptors interact with self peptide:self MHC complexes can survive and mature.	328
Questions.		290	8-20	Positive selection acts on a repertoire of T-cell receptors with inherent specificity for MHC molecules.	329
References.		291	8-21	Positive selection coordinates the expression of CD4 or CD8 with the specificity of the T-cell receptor and the potential effector functions of the T cell.	330
Chapter 8 The Development of B and T Lymphocytes	295		8-22	Thymic cortical epithelial cells mediate positive selection of developing thymocytes.	331
Development of B lymphocytes.	296		8-23	T cells that react strongly with ubiquitous self antigens are deleted in the thymus.	332
8-1	Lymphocytes derive from hematopoietic stem cells in the bone marrow.	297	8-24	Negative selection is driven most efficiently by bone marrow-derived antigen-presenting cells.	334
8-2	B-cell development begins by rearrangement of the heavy-chain locus.	299	8-25	The specificity and/or the strength of signals for negative and positive selection must differ.	334
8-3	The pre-B-cell receptor tests for successful production of a complete heavy chain and signals for the transition from the pro-B cell to the pre-B cell stage.	302	8-26	Self-recognizing regulatory T cells and innate T cells develop in the thymus.	335
8-4	Pre-B-cell receptor signaling inhibits further heavy-chain locus rearrangement and enforces allelic exclusion.	303	8-27	The final stage of T-cell maturation occurs in the thymic medulla.	336
8-5	Pre-B cells rearrange the light-chain locus and express cell-surface immunoglobulin.	304	8-28	T cells that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated.	336
8-6	Immature B cells are tested for autoreactivity before they leave the bone marrow.	305	Summary.	337	
8-7	Lymphocytes that encounter sufficient quantities of self antigens for the first time in the periphery are eliminated or inactivated.	308	Summary to Chapter 8.	337	
8-8	Immature B cells arriving in the spleen turn over rapidly and require cytokines and positive signals through the B-cell receptor for maturation and long-term survival.	309	Questions.	339	
8-9	B-1 B cells are an innate lymphocyte subset that arises early in development.	312	References.	340	
Summary.		313	PART IV THE ADAPTIVE IMMUNE RESPONSE	345	
Development of T lymphocytes.	315		Chapter 9 T-cell-Mediated Immunity	345	
8-10	T-cell progenitors originate in the bone marrow, but all the important events in their development occur in the thymus.	315	Development and function of secondary lymphoid organs—sites for the initiation of adaptive immune responses.	347	
8-11	Commitment to the T-cell lineage occurs in the thymus following Notch signaling.	317	9-1	T and B lymphocytes are found in distinct locations in secondary lymphoid tissues.	347
8-12	T-cell precursors proliferate extensively in the thymus, but most die there.	317	9-2	The development of secondary lymphoid tissues is controlled by lymphoid tissue inducer cells and proteins of the tumor necrosis factor family.	349
8-13	Successive stages in the development of thymocytes are marked by changes in cell-surface molecules.	319	9-3	T and B cells are partitioned into distinct regions of secondary lymphoid tissues by the actions of chemokines.	350
8-14	Thymocytes at different developmental stages are found in distinct parts of the thymus.	321	9-4	Naive T cells migrate through secondary lymphoid tissues, sampling peptide:MHC complexes on dendritic cells.	351
8-15	T cells with $\alpha\beta$ or $\gamma\delta$ receptors arise from a common progenitor.	322	9-5	Lymphocyte entry into lymphoid tissues depends on chemokines and adhesion molecules.	352
8-16	T cells expressing $\gamma\delta$ T-cell receptors arise in two distinct phases during development.	322	9-6	Activation of integrins by chemokines is responsible for the entry of naive T cells into lymph nodes.	353
8-17	Successful synthesis of a rearranged β chain allows the production of a pre-T-cell receptor that triggers cell proliferation and blocks further β -chain gene rearrangement.	324	9-7	The exit of T cells from lymph nodes is controlled by a chemotactic lipid.	355
			9-8	T-cell responses are initiated in secondary lymphoid organs by activated dendritic cells.	356
			9-9	Dendritic cells process antigens from a wide array of pathogens.	358

9-10	Microbe-induced TLR signaling in tissue-resident dendritic cells induces their migration to lymphoid organs and enhances antigen processing.	361	9-32	Cytotoxic T cells are selective serial killers of targets expressing a specific antigen.	391
9-11	Plasmacytoid dendritic cells produce abundant type I interferons and may act as helper cells for antigen presentation by conventional dendritic cells.	363	9-33	Cytotoxic T cells also act by releasing cytokines.	392
9-12	Macrophages are scavenger cells that can be induced by pathogens to present foreign antigens to naive T cells.	363		Summary.	392
9-13	B cells are highly efficient at presenting antigens that bind to their surface immunoglobulin.	364		Summary to Chapter 9.	392
	Summary.	366		Questions.	393
	Priming of naive T cells by pathogen-activated dendritic cells.	366		References.	395
9-14	Cell-adhesion molecules mediate the initial interaction of naive T cells with antigen-presenting cells.	367		Chapter 10 The Humoral Immune Response	399
9-15	Antigen-presenting cells deliver multiple signals for the clonal expansion and differentiation of naive T cells.	368		B-cell activation by antigen and helper T cells.	400
9-16	CD28-dependent co-stimulation of activated T cells induces expression of interleukin-2 and the high-affinity IL-2 receptor.	368	10-1	Activation of B cells by antigen involves signals from the B-cell receptor and either T _{FH} cells or microbial antigens.	400
9-17	Additional co-stimulatory pathways are involved in T-cell activation.	369	10-2	Linked recognition of antigen by T cells and B cells promotes robust antibody responses.	402
9-18	Proliferating T cells differentiate into effector T cells that do not require co-stimulation to act.	370	10-3	B cells that encounter their antigens migrate toward the boundaries between B-cell and T-cell areas in secondary lymphoid tissues.	403
9-19	CD8 T cells can be activated in different ways to become cytotoxic effector cells.	372	10-4	T cells express surface molecules and cytokines that activate B cells, which in turn promote T _{FH} -cell development.	406
9-20	CD4 T cells differentiate into several subsets of functionally different effector cells.	372	10-5	Activated B cells differentiate into antibody-secreting plasmablasts and plasma cells.	406
9-21	Cytokines induce the differentiation of naive CD4 T cells down distinct effector pathways.	375	10-6	The second phase of a primary B-cell immune response occurs when activated B cells migrate into follicles and proliferate to form germinal centers.	408
9-22	CD4 T-cell subsets can cross-regulate each other's differentiation through the cytokines they produce.	377	10-7	Germinal center B cells undergo V-region somatic hypermutation, and cells with mutations that improve affinity for antigen are selected.	410
9-23	Regulatory CD4 T cells are involved in controlling adaptive immune responses.	379	10-8	Positive selection of germinal center B cells involves contact with T _{FH} cells and CD40 signaling.	412
	Summary.	380	10-9	Activation-induced cytidine deaminase (AID) introduces mutations into genes transcribed in B cells.	413
	General properties of effector T cells and their cytokines.	380	10-10	Mismatch and base-excision repair pathways contribute to somatic hypermutation following initiation by AID.	414
9-24	Effector T-cell interactions with target cells are initiated by antigen-nonspecific cell-adhesion molecules.	381	10-11	AID initiates class switching to allow the same assembled V _H exon to be associated with different C _H genes in the course of an immune response.	415
9-25	An immunological synapse forms between effector T cells and their targets to regulate signaling and to direct the release of effector molecules.	381	10-12	Cytokines made by T _{FH} cells direct the choice of isotype for class switching in T-dependent antibody responses.	418
9-26	The effector functions of T cells are determined by the array of effector molecules that they produce.	383	10-13	B cells that survive the germinal center reaction eventually differentiate into either plasma cells or memory cells.	419
9-27	Cytokines can act locally or at a distance.	383	10-14	Some antigens do not require T-cell help to induce B-cell responses.	419
9-28	T cells express several TNF-family cytokines as trimeric proteins that are usually associated with the cell surface.	386		Summary.	421
	Summary.	386		The distributions and functions of immunoglobulin classes.	422
	T-cell-mediated cytotoxicity.	387	10-15	Antibodies of different classes operate in distinct places and have distinct effector functions.	423
9-29	Cytotoxic T cells induce target cells to undergo programmed cell death via extrinsic and intrinsic pathways of apoptosis.	387	10-16	Polymeric immunoglobulin receptor binds to the Fc regions of IgA and IgM and transports them across epithelial barriers.	425
9-30	The intrinsic pathway of apoptosis is mediated by the release of cytochrome c from mitochondria.	389	10-17	The neonatal Fc receptor carries IgG across the placenta and prevents IgG excretion from the body.	426
9-31	Cytotoxic effector proteins that trigger apoptosis are contained in the granules of CD8 cytotoxic T cells.	390			

10-18	High-affinity IgG and IgA antibodies can neutralize toxins and block the infectivity of viruses and bacteria.	426	11-11	Differentiated effector T cells continue to respond to signals as they carry out their effector functions.	466
10-19	Antibody:antigen complexes activate the classical pathway of complement by binding to C1q.	429	11-12	Effector T cells can be activated to release cytokines independently of antigen recognition.	467
10-20	Complement receptors and Fc receptors both contribute to removal of immune complexes from the circulation.	430	11-13	Effector T cells demonstrate plasticity and cooperativity that enable adaptation during anti-pathogen responses.	468
Summary.		431	11-14	Integration of cell- and antibody-mediated immunity is critical for protection against many types of pathogens.	469
The destruction of antibody-coated pathogens via Fc receptors.		432	11-15	Primary CD8 T-cell responses to pathogens can occur in the absence of CD4 T-cell help.	470
10-21	The Fc receptors of accessory cells are signaling receptors specific for immunoglobulins of different classes.	432	11-16	Resolution of an infection is accompanied by the death of most of the effector cells and the generation of memory cells.	471
10-22	Fc receptors on phagocytes are activated by antibodies bound to the surface of pathogens and enable the phagocytes to ingest and destroy pathogens.	433	Summary.		472
10-23	Fc receptors activate NK cells to destroy antibody-coated targets.	435	Immunological memory.		473
10-24	Mast cells and basophils bind IgE antibody via the high-affinity Fc ϵ receptor.	436	11-17	Immunological memory is long lived after infection or vaccination.	473
10-25	IgE-mediated activation of accessory cells has an important role in resistance to parasite infection.	437	11-18	Memory B-cell responses are more rapid and have higher affinity for antigen compared with responses of naive B cells.	475
Summary.		438	11-19	Memory B cells can reenter germinal centers and undergo additional somatic hypermutation and affinity maturation during secondary immune responses.	476
Summary to Chapter 10.		439	11-20	MHC tetramers identify memory T cells that persist at an increased frequency relative to their frequency as naive T cells.	477
Questions.		440	11-21	Memory T cells arise from effector T cells that maintain sensitivity to IL-7 or IL-15.	478
References.		441	11-22	Memory T cells are heterogeneous and include central memory, effector memory, and tissue-resident subsets.	480
Chapter 11 Integrated Dynamics of Innate and Adaptive Immunity		445	11-23	CD4 T-cell help is required for CD8 T-cell memory and involves CD40 and IL-2 signaling.	482
Integration of innate and adaptive immunity in response to specific types of pathogens.		446	11-24	In immune individuals, secondary and subsequent responses are mainly attributable to memory lymphocytes.	484
11-1	The course of an infection can be divided into several distinct phases.	446	Summary.		485
11-2	The effector mechanisms that are recruited to clear an infection depend on the infectious agent.	449	Summary to Chapter 11.		486
Summary.		452	Questions.		487
Effector T cells augment the effector functions of innate immune cells.		452	References.		488
11-3	Effector T cells are guided to specific tissues and sites of infection by changes in their expression of adhesion molecules and chemokine receptors.	453	Chapter 12 The Mucosal Immune System		493
11-4	Pathogen-specific effector T cells are enriched at sites of infection as adaptive immunity progresses.	457	The nature and structure of the mucosal immune system.		493
11-5	T _H 1 cells coordinate and amplify the host response to intracellular pathogens through classical activation of macrophages.	458	12-1	The mucosal immune system protects the internal surfaces of the body.	493
11-6	Activation of macrophages by T _H 1 cells must be tightly regulated to avoid tissue damage.	460	12-2	Cells of the mucosal immune system are located both in anatomically defined compartments and scattered throughout mucosal tissues.	496
11-7	Chronic activation of macrophages by T _H 1 cells mediates the formation of granulomas to contain intracellular pathogens that cannot be cleared.	461	12-3	The intestine has distinctive routes and mechanisms of antigen uptake.	499
11-8	Defects in type 1 immunity reveal its important role in the elimination of intracellular pathogens.	461	12-4	The mucosal immune system contains large numbers of effector lymphocytes even in the absence of disease.	500
11-9	T _H 2 cells coordinate type 2 responses to expel intestinal helminths and repair tissue injury.	462	12-5	The circulation of lymphocytes within the mucosal immune system is controlled by tissue-specific adhesion molecules and chemokine receptors.	501
11-10	T _H 17 cells coordinate type 3 responses to enhance the clearance of extracellular bacteria and fungi.	465			

12-6	Priming of lymphocytes in one mucosal tissue may induce protective immunity at other mucosal surfaces.	502	13-4	SCID can also be due to defects in the purine salvage pathway.	538
12-7	Distinct populations of dendritic cells control mucosal immune responses.	503	13-5	Defects in antigen receptor gene rearrangement can result in SCID.	538
12-8	Macrophages and dendritic cells have different roles in mucosal immune responses.	505	13-6	Defects in signaling from T-cell antigen receptors can cause severe immunodeficiency.	539
12-9	Antigen-presenting cells in the intestinal mucosa acquire antigen by a variety of routes.	505	13-7	Genetic defects in thymic function that block T-cell development result in severe immunodeficiencies.	539
12-10	Secretory IgA is the class of antibody associated with the mucosal immune system.	506	13-8	Defects in B-cell development result in deficiencies in antibody production that cause an inability to clear extracellular bacteria and some viruses.	541
12-11	T-independent processes can contribute to IgA production in some species.	509	13-9	Immune deficiencies can be caused by defects in B-cell or T-cell activation and function that lead to abnormal antibody responses.	543
12-12	IgA deficiency is relatively common in humans but may be compensated for by secretory IgM.	509	13-10	Normal pathways for host defense against different infectious agents are pinpointed by genetic deficiencies of cytokine pathways central to type 1/T _H 1 and type 3/T _H 17 responses.	546
12-13	The intestinal lamina propria contains antigen-experienced T cells and populations of unusual innate lymphoid cells.	510	13-11	Inherited defects in the cytolytic pathway of lymphocytes can cause uncontrolled lympho-proliferation and inflammatory responses to viral infections.	548
12-14	The intestinal epithelium is a unique compartment of the immune system.	511	13-12	X-linked lymphoproliferative syndrome is associated with fatal infection by Epstein–Barr virus and with the development of lymphomas.	550
Summary.		514	13-13	Immunodeficiency is caused by inherited defects in the development of dendritic cells.	551
The mucosal response to infection and regulation of mucosal immune responses.		514	13-14	Defects in complement components and complement-regulatory proteins cause defective humoral immune function and tissue damage.	552
12-15	Enteric pathogens cause a local inflammatory response and the development of protective immunity.	515	13-15	Defects in phagocytic cells permit widespread bacterial infections.	553
12-16	Pathogens induce adaptive immune responses when innate defenses have been breached.	518	13-16	Mutations in the molecular regulators of inflammation can cause uncontrolled inflammatory responses that result in 'autoinflammatory disease.'	556
12-17	Effector T-cell responses in the intestine protect the function of the epithelium.	518	13-17	Hematopoietic stem cell transplantation or gene therapy can be useful to correct genetic defects.	557
12-18	The mucosal immune system must maintain tolerance to harmless foreign antigens.	519	13-18	Noninherited, secondary immunodeficiencies are major predisposing causes of infection and death.	558
12-19	The normal intestine contains large quantities of bacteria that are required for health.	520	Summary.		559
12-20	Innate and adaptive immune systems control microbiota while preventing inflammation without compromising the ability to react to invaders.	521	Evasion and subversion of immune defenses.		560
12-21	The intestinal microbiota plays a major role in shaping intestinal and systemic immune function.	522	13-19	Extracellular bacterial pathogens have evolved different strategies to avoid detection by pattern recognition receptors and destruction by antibody, complement, and antimicrobial peptides.	560
12-22	Full immune responses to commensal bacteria provoke intestinal disease.	524	13-20	Intracellular bacterial pathogens can evade the immune system by seeking shelter within phagocytes.	563
Summary.		525	13-21	Immune evasion is also practiced by protozoan parasites.	565
Summary to Chapter 12.		525	13-22	RNA viruses use different mechanisms of antigenic variation to keep a step ahead of the adaptive immune system.	566
Questions.		526	13-23	DNA viruses use multiple mechanisms to subvert NK-cell and CTL responses.	568
References.		527	13-24	Some latent viruses persist <i>in vivo</i> by ceasing to replicate until immunity wanes.	571
			Summary.		573
			Acquired immune deficiency syndrome.		573
			13-25	HIV is a retrovirus that establishes a chronic infection that slowly progresses to AIDS.	574

PART V THE IMMUNE SYSTEM IN HEALTH AND DISEASE

Chapter 13 Failures of Host Defense Mechanisms 533

Immunodeficiency diseases. 533

13-1	A history of repeated infections suggests a diagnosis of immunodeficiency.	534
13-2	Primary immunodeficiency diseases are caused by inherited gene defects.	534
13-3	Defects in T-cell development can result in severe combined immunodeficiencies.	535

13-26	HIV infects and replicates within cells of the immune system.	576	14-10	Allergen introduced into the bloodstream can cause anaphylaxis.	619
13-27	Activated CD4 T cells are the major source of HIV replication.	578	14-11	Allergen inhalation is associated with the development of rhinitis and asthma.	621
13-28	There are several routes by which HIV is transmitted and establishes infection.	579	14-12	Allergy to particular foods causes systemic reactions as well as symptoms limited to the gut.	624
13-29	HIV variants with tropism for different co-receptors play different roles in transmission and progression of disease.	580	14-13	IgE-mediated allergic disease can be treated by inhibiting the effector pathways that lead to symptoms or by desensitization techniques that aim at restoring biological tolerance to the allergen.	625
13-30	A genetic deficiency of the co-receptor CCR5 confers resistance to HIV infection.	582		Summary.	627
13-31	An immune response controls but does not eliminate HIV.	583		Non-IgE-mediated allergic diseases.	628
13-32	Lymphoid tissue is the major reservoir of HIV infection.	585	14-14	Non-IgE dependent drug-induced hypersensitivity reactions in susceptible individuals occur by binding of the drug to the surface of circulating blood cells.	628
13-33	Genetic variation in the host can alter the rate of disease progression.	585	14-15	Systemic disease caused by immune-complex formation can follow the administration of large quantities of poorly catabolized antigens.	628
13-34	The destruction of immune function as a result of HIV infection leads to increased susceptibility to opportunistic infection and eventually to death.	587	14-16	Hypersensitivity reactions can be mediated by T _H 1 cells and CD8 cytotoxic T cells.	630
13-35	Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells.	588	14-17	Celiac disease has features of both an allergic response and autoimmunity.	634
13-36	In the course of infection HIV accumulates many mutations, which can result in the outgrowth of drug-resistant variants.	590		Summary.	636
13-37	Vaccination against HIV is an attractive solution but poses many difficulties.	591		Summary to Chapter 14.	636
13-38	Prevention and education are important in controlling the spread of HIV and AIDS.	592		Questions.	637
	Summary.	593		References.	638
	Summary to Chapter 13.	594		Chapter 15 Autoimmunity and Transplantation	643
	Questions.	594		The making and breaking of self-tolerance.	643
	References.	595	15-1	A critical function of the immune system is to discriminate self from nonself.	643
	Chapter 14 Allergy and Allergic Diseases	601	15-2	Multiple tolerance mechanisms normally prevent autoimmunity.	645
	IgE and IgE-mediated allergic diseases.	602	15-3	Central deletion or inactivation of newly formed lymphocytes is the first checkpoint of self-tolerance.	646
14-1	Sensitization involves class switching to IgE production on first contact with an allergen.	603	15-4	Lymphocytes that bind self antigens with relatively low affinity usually ignore them but in some circumstances become activated.	647
14-2	Although many types of antigens can cause allergic sensitization, proteases are common sensitizing agents.	605	15-5	Antigens in immunologically privileged sites do not induce immune attack but can serve as targets.	648
14-3	Genetic factors contribute to the development of IgE-mediated allergic disease.	607	15-6	Autoreactive T cells that express particular cytokines may be nonpathogenic or may suppress pathogenic lymphocytes.	649
14-4	Environmental factors may interact with genetic susceptibility to cause allergic disease.	609	15-7	Autoimmune responses can be controlled at various stages by regulatory T cells.	650
14-5	Regulatory T cells can control allergic responses.	611		Summary.	652
	Summary.	612		Autoimmune diseases and pathogenic mechanisms.	652
	Effector mechanisms in IgE-mediated allergic reactions.	612	15-8	Specific adaptive immune responses to self antigens can cause autoimmune disease.	652
14-6	Most IgE is cell-bound and engages effector mechanisms of the immune system by pathways different from those of other antibody isotypes.	613	15-9	Autoimmunity can be classified into either organ-specific or systemic disease.	653
14-7	Mast cells reside in tissues and orchestrate allergic reactions.	613	15-10	Multiple components of the immune system are typically recruited in autoimmune disease.	654
14-8	Eosinophils and basophils cause inflammation and tissue damage in allergic reactions.	616	15-11	Chronic autoimmune disease develops through positive feedback from inflammation, inability to clear the self antigen, and a broadening of the autoimmune response.	657
14-9	IgE-mediated allergic reactions have a rapid onset but can also lead to chronic responses.	617			

15-12	Both antibody and effector T cells can cause tissue damage in autoimmune disease.	659	15-37	Regulatory T cells are involved in alloreactive immune responses.	692
15-13	Autoantibodies against blood cells promote their destruction.	661	15-38	The fetus is an allograft that is tolerated repeatedly.	693
15-14	The fixation of sublytic doses of complement to cells in tissues stimulates a powerful inflammatory response.	661		Summary.	694
15-15	Autoantibodies against receptors cause disease by stimulating or blocking receptor function.	662		Summary to Chapter 15.	694
15-16	Autoantibodies against extracellular antigens cause inflammatory injury.	663		Questions.	695
15-17	T cells specific for self antigens can cause direct tissue injury and sustain autoantibody responses.	665		References.	696
	Summary.	668			
	The genetic and environmental basis of autoimmunity.	669		Chapter 16 Manipulation of the Immune Response	701
15-18	Autoimmune diseases have a strong genetic component.	669		Treatment of unwanted immune responses.	701
15-19	Genomics-based approaches are providing new insight into the immunogenetic basis of autoimmunity.	670	16-1	Corticosteroids are powerful anti-inflammatory drugs that alter the transcription of many genes.	702
15-20	Many genes that predispose to autoimmunity fall into categories that affect one or more tolerance mechanisms.	674	16-2	Cytotoxic drugs cause immunosuppression by killing dividing cells and have serious side-effects.	703
15-21	Monogenic defects of immune tolerance.	674	16-3	Cyclosporin A, tacrolimus, rapamycin, and JAK inhibitors are effective immunosuppressive agents that interfere with various T-cell signaling pathways.	704
15-22	MHC genes have an important role in controlling susceptibility to autoimmune disease.	676	16-4	Antibodies against cell-surface molecules can be used to eliminate lymphocyte subsets or to inhibit lymphocyte function.	706
15-23	Genetic variants that impair innate immune responses can predispose to T-cell-mediated chronic inflammatory disease.	678	16-5	Antibodies can be engineered to reduce their immunogenicity in humans.	707
15-24	External events can initiate autoimmunity.	679	16-6	Monoclonal antibodies can be used to prevent allograft rejection.	708
15-25	Infection can lead to autoimmune disease by providing an environment that promotes lymphocyte activation.	680	16-7	Depletion of autoreactive lymphocytes can treat autoimmune disease.	710
15-26	Cross-reactivity between foreign molecules on pathogens and self molecules can lead to antiself responses and autoimmune disease.	680	16-8	Biologics that block TNF- α , IL-1, or IL-6 can alleviate autoimmune diseases.	711
15-27	Drugs and toxins can cause autoimmune syndromes.	682	16-9	Biologic agents can block cell migration to sites of inflammation and reduce immune responses.	712
15-28	Random events may be required for the initiation of autoimmunity.	682	16-10	Blockade of co-stimulatory pathways that activate lymphocytes can be used to treat autoimmune disease.	713
	Summary.	682	16-11	Some commonly used drugs have immunomodulatory properties.	713
	Responses to alloantigens and transplant rejection.	683	16-12	Controlled administration of antigen can be used to manipulate the nature of an antigen-specific response.	714
15-29	Graft rejection is an immunological response mediated primarily by T cells.	683		Summary.	714
15-30	Transplant rejection is caused primarily by the strong immune response to nonself MHC molecules.	684		Using the immune response to attack tumors.	716
15-31	In MHC-identical grafts, rejection is caused by peptides from other alloantigens bound to graft MHC molecules.	685	16-13	The development of transplantable tumors in mice led to the discovery of protective immune responses to tumors.	716
15-32	There are two ways of presenting alloantigens on the transplanted donor organ to the recipient's T lymphocytes.	686	16-14	Tumors are 'edited' by the immune system as they evolve and can escape rejection in many ways.	717
15-33	Antibodies that react with endothelium cause hyperacute graft rejection.	688	16-15	Tumor rejection antigens can be recognized by T cells and form the basis of immunotherapies.	720
15-34	Late failure of transplanted organs is caused by chronic injury to the graft.	688	16-16	T cells expressing chimeric antigen receptors are an effective treatment in some leukemias.	723
15-35	A variety of organs are transplanted routinely in clinical medicine.	689	16-17	Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth.	724
15-36	The converse of graft rejection is graft-versus-host disease.	691	16-18	Enhancing the immune response to tumors by vaccination holds promise for cancer prevention and therapy.	726
			16-19	Checkpoint blockade can augment immune responses to existing tumors.	727
				Summary.	728

Fighting infectious diseases with vaccination.

16-20	Vaccines can be based on attenuated pathogens or material from killed organisms.	729
16-21	Most effective vaccines generate antibodies that prevent the damage caused by toxins or that neutralize the pathogen and stop infection.	730
16-22	Effective vaccines must induce long-lasting protection while being safe and inexpensive.	731
16-23	Live-attenuated viral vaccines are usually more potent than 'killed' vaccines and can be made safer by the use of recombinant DNA technology.	732
16-24	Live-attenuated vaccines can be developed by selecting nonpathogenic or disabled bacteria or by creating genetically attenuated parasites (GAPs).	734
16-25	The route of vaccination is an important determinant of success.	735
16-26	<i>Bordetella pertussis</i> vaccination illustrates the importance of the perceived safety of a vaccine.	736
16-27	Conjugate vaccines have been developed as a result of linked recognition between T and B cells.	737
16-28	Peptide-based vaccines can elicit protective immunity, but they require adjuvants and must be targeted to the appropriate cells and cell compartment to be effective.	738
16-29	Adjuvants are important for enhancing the immunogenicity of vaccines, but few are approved for use in humans.	739
16-30	Protective immunity can be induced by DNA-based vaccination.	740
16-31	Vaccination and checkpoint blockade may be useful in controlling existing chronic infections.	741
	Summary.	742
	Summary to Chapter 16.	742
	Questions.	743
	References.	744

APPENDICES

Appendix I The Immunologist's Toolbox

A-1.	Immunization.	749
A-2	Antibody responses.	749
A-3	Affinity chromatography.	752
A-4	Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and competitive inhibition assay.	753
A-5	Hemagglutination and blood typing.	753
A-6	Coombs tests and the detection of rhesus incompatibility.	755
A-7	Monoclonal antibodies.	756
A-8	Phage display libraries for antibody V-region production.	757
A-9	Generation of human monoclonal antibodies from vaccinated individuals.	758
A-10	Microscopy and imaging using fluorescent dyes.	759
A-11	Immunoelectron microscopy.	760
A-12	Immunohistochemistry.	761
A-13	Immunoprecipitation and co-immunoprecipitation.	762

A-14	Immunoblotting (Western blotting).	764
A-15	Use of antibodies in the isolation and characterization of multiprotein complexes by mass spectrometry.	764
A-16	Isolation of peripheral blood lymphocytes by density-gradient fractionation.	766
A-17	Isolation of lymphocytes from tissues other than blood.	766
A-18	Flow cytometry and FACS analysis.	767
A-19	Lymphocyte isolation using antibody-coated magnetic beads.	770
A-20	Isolation of homogeneous T-cell lines.	770
A-21	Limiting-dilution culture.	771
A-22	ELISPOT assay.	773
A-23	Identification of functional subsets of T cells based on cytokine production or transcription factor expression.	773
A-24	Identification of T-cell receptor specificity using peptide:MHC tetramers.	776
A-25	Biosensor assays for measuring the rates of association and dissociation of antigen receptors for their ligands.	777
A-26	Assays of lymphocyte proliferation.	778
A-27	Measurements of apoptosis.	779
A-28	Assays for cytotoxic T cells.	780
A-29	Assays for CD4 T cells.	782
A-30	Transfer of protective immunity.	782
A-31	Adoptive transfer of lymphocytes.	783
A-32	Hematopoietic stem-cell transfers.	784
A-33	<i>In vivo</i> administration of antibodies.	785
A-34	Transgenic mice.	786
A-35	Gene knockout by targeted disruption.	786
A-36	Knockdown of gene expression by RNA interference (RNAi).	790

Appendix II	CD antigens	791
-------------	-------------	-----

Appendix III	Cytokines and their Receptors	811
--------------	-------------------------------	-----

Appendix IV	Chemokines and their Receptors	814
-------------	--------------------------------	-----

Biographies	816
-------------	-----

Photograph Acknowledgments	817
----------------------------	-----

Glossary	818
----------	-----

Index	855
-------	-----


dendritic cells). This results in heightened susceptibility to intracellular bacteria, particularly atypical *Mycobacterium* spp., without the myeloproliferative syndrome seen in patients with the autosomal recessive variant.

13-14 Defects in complement components and complement-regulatory proteins cause defective humoral immune function and tissue damage.

The diseases discussed so far are mainly due to disturbances of the adaptive immune system. In the next few sections we look at some immunodeficiency diseases that affect cells and molecules of the innate immune system. We start with the complement system, which can be activated by any of three pathways that converge on the cleavage and activation of complement component C3, allowing it to bind covalently to pathogen surfaces, where it acts as an opsonin (discussed in Chapter 2). Not surprisingly, the spectrum of infections associated with complement deficiencies overlaps substantially with that seen in patients with deficiencies in antibody production. In particular, there is increased susceptibility to extracellular bacteria that require opsonization by antibody and/or complement for efficient clearance by phagocytes (Fig. 13.11). Defects in the activation of C3 by any of the three pathways, as well as defects in C3 itself, are associated with increased susceptibility to infection by a range of pyogenic bacteria, including *S. pneumoniae*, emphasizing the role of C3 as a central effector that promotes the phagocytosis and clearance of capsulated bacteria.

In contrast, defects in the membrane-attack components of complement (C5-C9) downstream of C3 activation have more limited effects, and result almost exclusively in susceptibility to *Neisseria* species. A similar susceptibility to *Neisseria* species is found in patients with defects in the alternative complement pathway components factor D and properdin, indicating that defense against these bacteria, which can survive intracellularly, is largely mediated via antibody-independent extracellular lysis by the membrane-attack complex. Data from large-population studies in Japan, where endemic *N. meningitidis* infection is rare, show that the risk each year of infection with this organism

Fig. 13.11 Defects in complement components are associated with susceptibility to certain infections and the accumulation of immune complexes. Defects in the early components of the alternative pathway and in C3 lead to susceptibility to extracellular pathogens, particularly pyogenic bacteria. Defects in the early components of the classical pathway predominantly affect the processing of immune complexes (see Section 10-20) and the clearance of apoptotic cells, leading to immune-complex disease. Deficiency of mannose-binding lectin (MBL), the recognition molecule of the mannose-binding lectin pathway, is associated with bacterial infections, mainly in early childhood. Defects in the membrane-attack components are associated only with susceptibility to strains of *Neisseria* species, the causative agents of meningitis and gonorrhea, implying that the effector pathway is important chiefly in defense against these organisms.



is approximately 1 in 2,000,000 to a normal person. This compares with a risk of 1 in 200 to a person in the same population with an inherited deficiency of one of the membrane-attack complex proteins—a 10,000-fold increase in risk.

The early components of the classical complement pathway are particularly important for the elimination of immune complexes (discussed in Section 10-20) and apoptotic cells, which can cause significant pathology in autoimmune diseases such as systemic lupus erythematosus. This aspect of inherited complement deficiency is discussed in Chapter 15. Deficiencies in mannose-binding lectin (MBL), which initiates complement activation independently of antibody (see Section 2-6), are relatively common (found in 5% of the population). MBL deficiency may be associated with a mild immunodeficiency that results in an increased incidence of bacterial infection in early childhood. A similar phenotype is found in patients with defects in the gene that encodes the MBL-associated serine protease-2 (*MASP2*).

Another set of complement-related diseases is caused by defects in complement-control proteins (Fig. 13.12). Deficiencies in decay-accelerating factor (DAF) or protectin (CD59), membrane-associated control proteins that protect the surfaces of the body's cells from complement activation, lead to destruction of red blood cells, resulting in the disease **paroxysmal nocturnal hemoglobinuria**, as discussed in Section 2-16. Deficiencies in soluble complement-regulatory proteins such as factor I and factor H have various outcomes. Homozygous **factor I deficiency** is a rare defect that results in uncontrolled activity of the alternative pathway C3 convertase, leading to a *de facto* C3 deficiency (see Section 2-16). Deficiencies in MCP, factor I, or factor H can also cause a condition known as **atypical hemolytic-uremic syndrome**, so called because it leads to lysis of red blood cells (hemolysis) and impaired kidney function (uremia).

A striking consequence of the loss of a complement-regulatory protein is seen in patients with C1-inhibitor defects, which cause the syndrome known as **hereditary angioedema (HAE)** (see Section 2-16). Deficiency of C1 inhibitor results in a failure to regulate both the blood clotting and complement activation pathways, leading to excessive production of vasoactive mediators that cause fluid accumulation in the tissues (edema) and local laryngeal swelling that can result in suffocation.

13-15 Defects in phagocytic cells permit widespread bacterial infections.

Deficiencies in phagocyte numbers or function can be associated with severe immunodeficiency; indeed, a total absence of neutrophils is incompatible with survival in a normal environment. Phagocyte immunodeficiencies can be grouped into four general types: deficiencies in phagocyte production, phagocyte adhesion, phagocyte activation, and phagocyte killing of microorganisms (Fig. 13.13). We consider each in turn.

Inherited deficiencies of neutrophil production (**neutropenias**) are classified either as **severe congenital neutropenia (SCN)** or **cyclic neutropenia**. In severe congenital neutropenia, which can be inherited as a dominant or recessive trait, the neutrophil count is persistently less than 0.5×10^9 per liter of blood (normal numbers are 3×10^9 to 5.5×10^9 per liter). Cyclic neutropenia is characterized by fluctuation in neutrophil numbers from near normal to very low or undetectable with an approximate cycle time of 21 days, resulting in periodicity of infectious risk. The most common causes of SCN are sporadic or autosomal dominant mutations of the gene that encodes neutrophil elastase (*ELA2*), a component of the azurophilic, or primary, granules involved in the degradation of phagocytosed microbes. Altered targeting of defective elastase 2 to granules causes apoptosis of developing myelocytes and a developmental block at the promyelocyte-myelocyte stage. Some mutations of *ELA2* cause

Complement protein	Effects of deficiency
C1, C2, C4	Immune-complex disease
C3	Susceptibility to encapsulated bacteria
C5–C9	Susceptibility to <i>Neisseria</i>
Factor D, properdin (factor P)	Susceptibility to encapsulated bacteria and <i>Neisseria</i> but no immune-complex disease
Factor I	Similar effects to deficiency of C3
MCP, factor I or factor H	Atypical hemolytic-uremic syndrome
Polymorphisms in factor H	Age-related macular degeneration
DAF, CD59	Autoimmune-like conditions, including paroxysmal nocturnal hemoglobinuria
C1INH	Hereditary angioedema (HAE)

Fig. 13.12 Defects in complement-control proteins are associated with a range of diseases.

Fig. 13.13 Defects in phagocytic cells are associated with persistence of bacterial infection. Defects in neutrophil development caused by congenital neutropenias result in profound defects in antibacterial defense. Impairment of the leukocyte integrins with a common β_2 subunit (CD18) or defects in the selectin ligand sialyl-Lewis^x, prevent phagocytic cell adhesion and migration to sites of infection (leukocyte adhesion deficiency). Inability to transmit signals through Toll-like receptors (TLRs), due to defects in MyD88 or IRAK4, for example, impairs the proximal sensing of many infectious agents by innate immune cells. The respiratory burst is defective in chronic granulomatous disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and myeloperoxidase deficiency. In chronic granulomatous disease, infections persist because macrophage activation is defective, leading to chronic stimulation of CD4 T cells and hence to granulomas. Vesicle fusion in phagocytes is defective in Chediak–Higashi syndrome. These diseases illustrate the critical role of phagocytes in removing and killing pathogenic bacteria.

Type of defect/name of syndrome	Associated infections or other diseases
Congenital neutropenias (e.g., elastase 2 deficiency)	Widespread pyogenic bacterial infections
Leukocyte adhesion deficiency	Widespread pyogenic bacterial infections
TLR signaling defects (e.g., MyD88 or IRAK4)	Severe cold pyogenic bacterial infections
Chronic granulomatous disease	Intracellular and extracellular infection, granulomas
G6PD deficiency	Defective respiratory burst, chronic infection
Myeloperoxidase deficiency	Defective intracellular killing, chronic infection
Chediak–Higashi syndrome	Intracellular and extracellular infection, granulomas

cyclic neutropenia; how the mutant elastase causes a 21-day cycle in neutropenia is still a mystery. A rare autosomal dominant form of SCN is caused by mutations in the oncogene *GFI1*, which encodes a transcriptional repressor that acts on *ELA2*. This finding arose from the unexpected observation that mice lacking the protein Gfi1 are neutropenic due to overexpression of *Ela2*.

Autosomal recessive forms of SCN have also been identified. Deficiency of the mitochondrial protein HAX1 leads to increased apoptosis in developing myeloid cells, resulting in a severe neutropenia referred to as **Kostmann's disease**. The heightened sensitivity of developing neutrophils to apoptosis is highlighted by SCN associated with genetic defects in glucose metabolism. Patients with recessive mutations in the genes encoding the glucose-6-phosphatase catalytic subunit 3 (*G6PC3*) or the glucose-6-phosphate translocase 1 (*SLC37A4*) also demonstrate increased apoptosis during granulocyte development that results in neutropenia. Acquired neutropenia associated with chemotherapy, malignancy, or aplastic anemia is also associated with a similar spectrum of severe pyogenic bacterial infections. Finally, neutropenia can also be a feature of other primary immunodeficiency diseases, including CD40 ligand deficiency, CVID, XLA, Wiskott–Aldrich syndrome, and GATA2 deficiency. Some patients exhibit formation of autoantibodies that lead to accelerated destruction of neutrophils.

Defects in the migration of phagocytic cells to extravascular sites of infection can cause serious immunodeficiency. Leukocytes reach such sites by emigrating from blood vessels in a tightly regulated process (see Fig. 3.31). Deficiencies in the molecules involved in each stage of this process can prevent neutrophils and macrophages from penetrating infected tissues, and are referred to as **leukocyte adhesion deficiencies (LADs)**. Deficiency in the leukocyte integrin common β_2 subunit CD18, which is a component of LFA-1, MAC-1, and p150:95, prevents the migration of leukocytes into an infected site by abolishing the cells' ability to adhere tightly to the endothelium. Because it was the first LAD to be characterized, it is now referred to as type 1 LAD, or LAD-1, and is the most common LAD variant. Reduced rolling of leukocytes on the endothelium has been described in rare patients who lack the sialyl-Lewis^x antigen owing to a deficiency in the GDP-fucose-specific transporter that is involved in the biosynthesis of sialyl-Lewis^x and other fucosylated ligands for the selectins. This is referred to as type 2 LAD or LAD-2. LAD-3 results from deficiency of Kindlin-3, a protein involved in the induction of the high-affinity binding state of β integrins required for firm adhesion. Each variant of LAD has an autosomal recessive pattern of inheritance and causes severe, life-threatening bacterial or fungal infections early in life that are characterized by impaired wound healing and, in pyogenic bacterial infections, the absence of